Literature DB >> 11455013

Stimulation of leukotriene synthesis in intact polymorphonuclear cells by the 5-lipoxygenase inhibitor 3-oxo-tirucallic acid.

S E Boden1, S Schweizer, T Bertsche, M Düfer, G Drews, H Safayhi.   

Abstract

Commercially available extracts from Boswellia serrata resin used as anti-inflammatory drugs or phytonutrients show paradoxical concentration-dependent potentiating and inhibitory actions on 5-lipoxygenase (5-LO) product synthesis in stimulated PMNs. In our attempt to characterize the stimulating constituents, we identified the tetracyclic triterpene 3-oxo-tirucallic acid (3-oxo-TA), which, in the range from 2.5 to 15 microM, enhanced 5-LO product formation in ionophore-challenged polymorphonuclear cells (PMNs) (e.g., from 1981 +/- 177 to 3042 +/- 208 pmol at 10 microM 3-oxo-TA), and initiated Ca(2+) mobilization, MEK-1/2 phosphorylation, 5-LO translocation, and 5-LO product formation in resting cells (534 +/- 394 pmol/5 x 10(6) PMNs). In cell-free 5-LO assays, 3-oxo-TA acted only inhibitory (IC(50) value of about 3 microM), demonstrating the pivotal role of intact cell structure for its activating property. In 3-oxo-TA-challenged PMNs, the mitogen-activated protein kinase kinase (MEK)-1/2 inhibitor PD098059 abolished 5-LO product formation, along with inhibition of MEK-1/2 phosphorylation and 5-LO translocation. The 3-acetoxy derivative of 3-oxo-TA acted like 3-oxo-TA in intact PMNs, whereas 3-hydroxy-TA barely stimulated MEK phosphorylation in resting cells and showed only inhibition on ionophore-induced 5-LO product synthesis. Steroid-type tetracycles neither induced 5-LO activation nor had enhancing or inhibitory effects. In summary, defined natural tetracyclic triterpenes, which act as inhibitors of the 5-LO in the cell-free assay, initiate 5-LO activation by a MEK-inhibitor sensitive mechanism and potentiate stimulated product synthesis in intact cells. Because TAs contribute significantly to the overall biological effects of B. serrata resin extracts, special precaution for standardization is recommended when using B. serrata preparations as drugs or dietary supplements.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11455013     DOI: 10.1124/mol.60.2.267

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  7 in total

1.  Triterpenoid resinous metabolites from the genus Boswellia: pharmacological activities and potential species-identifying properties.

Authors:  Yuxin Zhang; Zhangchi Ning; Cheng Lu; Siyu Zhao; Jianfen Wang; Baoqin Liu; Xuegong Xu; Yuanyan Liu
Journal:  Chem Cent J       Date:  2013-09-12       Impact factor: 4.215

Review 2.  Boswellia serrata: an overall assessment of in vitro, preclinical, pharmacokinetic and clinical data.

Authors:  Mona Abdel-Tawab; Oliver Werz; Manfred Schubert-Zsilavecz
Journal:  Clin Pharmacokinet       Date:  2011-06       Impact factor: 6.447

3.  Coupling of boswellic acid-induced Ca2+ mobilisation and MAPK activation to lipid metabolism and peroxide formation in human leucocytes.

Authors:  Anja Altmann; Daniel Poeckel; Lutz Fischer; Manfred Schubert-Zsilavecz; Dieter Steinhilber; Oliver Werz
Journal:  Br J Pharmacol       Date:  2003-12-22       Impact factor: 8.739

4.  Tetra- and pentacyclic triterpene acids from the ancient anti-inflammatory remedy frankincense as inhibitors of microsomal prostaglandin E(2) synthase-1.

Authors:  Moritz Verhoff; Stefanie Seitz; Michael Paul; Stefan M Noha; Johann Jauch; Daniela Schuster; Oliver Werz
Journal:  J Nat Prod       Date:  2014-05-20       Impact factor: 4.050

5.  Triterpene Acids from Frankincense and Semi-Synthetic Derivatives That Inhibit 5-Lipoxygenase and Cathepsin G.

Authors:  Andreas Koeberle; Arne Henkel; Moritz Verhoff; Lars Tausch; Stefanie König; Dagmar Fischer; Nicole Kather; Stefanie Seitz; Michael Paul; Johann Jauch; Oliver Werz
Journal:  Molecules       Date:  2018-02-24       Impact factor: 4.411

6.  Safety and efficacy of a feed additive consisting of an extract of olibanum from Boswellia serrata Roxb. ex Colebr. for use in dogs and horses (FEFANA asbl).

Authors:  Vasileios Bampidis; Giovanna Azimonti; Maria de Lourdes Bastos; Henrik Christensen; Mojca Fašmon Durjava; Maryline Kouba; Marta López-Alonso; Secundino López Puente; Francesca Marcon; Baltasar Mayo; Alena Pechová; Mariana Petkova; Fernando Ramos; Yolanda Sanz; Roberto Edoardo Villa; Ruud Woutersen; Paul Brantom; Andrew Chesson; Johannes Westendorf; Paola Manini; Fabiola Pizzo; Birgit Dusemund
Journal:  EFSA J       Date:  2022-03-07

7.  Estimation of boswellic acids in herbal formulations containing Boswellia serrata extract and comprehensive characterization of secondary metabolites using UPLC-Q-Tof-MSe.

Authors:  Kumar Katragunta; Bandi Siva; Niharika Kondepudi; P R Rao Vadaparthi; Nadendla Rama Rao; Ashok Kumar Tiwari; Katragadda Suresh Babu
Journal:  J Pharm Anal       Date:  2019-10-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.